Dietary Supplement 4-Methylumbelliferone: An Effective Chemopreventive and Therapeutic Agent for Prostate Cancer

Journal of the National Cancer Institute

Volumn 107, Issue 7, 2015, Pages

  Yates, Travis J ^a,d   Lopez, Luis E ^b   Lokeshwar, Soum D ^c   Ortiz, Nicolas ^b   Kallifatidis, Georgios ^b   Jordan, Andre ^a   Hoye, Kelly ^a   Altman, Norman ^c   Lokeshwar, Vinata B ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Department of Pathology ^*  (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYMECROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; HYALURONIC ACID; TUMOR MARKER;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER PREVENTION; CANCER THERAPY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CANCER STAGING; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HYALURONIC ACID; HYMECROMONE; MALE; MICE; MICE, NUDE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84937138227     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv085     Document Type: Article

References (66)

1. Adamia S, Pilarski PM, Belch AR, et al. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. Curr Cancer Drug Targets. 2013;13(4):347-361.
2. Simpson MA, Lokeshwar VB. Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci. 2008;13:5664-5680.
3. Sironen RK, Tammi M, Tammi R, et al. Hyaluronan in human malignancies. Exp Cell Res. 2011;317(4):383-391.
4. Auvinen P, Rilla K, Tumelius R, et al. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat. 2014;143(2):277-286.
5. Bouga H, Tsouros I, Bounias D, et al. Involvement of hyaluronidases in colorectal cancer. BMC Cancer. 2010;10:499.
6. Chi A, Shirodkar SP, Escudero DO, et al. Molecular characterization of kidney cancer: Association of hyaluronic acid family with histological subtypes and metastasis. Cancer. 2012;118(9):2394-2402.
7. Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. 2011;117(6):1197-1209.
8. Ekici S, Cerwinka WH, Duncan R, et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer. 2004;112(1):121-129.
9. Gomez CS, Gomez P, Knapp J, et al. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol. 2009;182(4):1350-1356.
10. Benitez A, Yates TJ, Lopez LE, et al. Targeting hyaluronidase for cancer therapy: Antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011;71(12):4085-4095.
11. Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/ RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285(47):36721-36735.
12. Darzynkiewicz Z, Balazs EA. Genome integrity, stem cells and hyaluronan. Aging (Albany NY). 2012;4(2):78-88.
13. Karbownik MS, Nowak JZ. Hyaluronan: Towards novel anti-cancer therapeutics. Pharmacol Rep. 2013;65(5):1056-1074.
14. Lokeshwar VBM, Mirza S, Jordan A. Targeting Hyaluronic family for Cancer chemoprevention and therapy. Adv Cancer Res. 2014;123:35-65.
15. Williams K, Motiani K, Giridhar PV, et al. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013;238(3):324-338.
16. Bharadwaj AG, Kovar JL, Loughman E, et al. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol. 2009;174(3):1027-1036.
17. Bharadwaj AG, Rector K, Simpson MA. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J Biol Chem. 2007;282(28):20561-20572.
18. Ghosh A, Kuppusamy H, Pilarski LM. Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: A potential mechanism promoting human cancer. J Biol Chem. 2009;284(28):18840-18850.
19. Golshani R, Lopez L, Estrella V, et al. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008;68(2):483-491.
20. Lokeshwar VB, Cerwinka WH, Isoyama T, et al. HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor. Cancer Res. 2005;65(17):7782- 7789.
21. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 hyaluronidase: A molecular determinant of bladder tumor growth and invasion. Cancer Res. 2005;65(6):2243-2250.
22. Okuda H, Kobayashi A, Xia B, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 2012;72(2):537-547.
23. Arai E, Nishida Y, Wasa J, et al. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 2011;105(12):1839-1849.
24. Bhattacharyya SS, Paul S, Mandal SK, et al. A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. Eur J Pharmacol. 2009;614(1-3):128-136.
25. Piccioni F, Malvicini M, Garcia MG, et al. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology. 2012;22(3):400-410.
26. Urakawa H, Nishida Y, Wasa J, et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 2012;130(2):454- 466.
27. Yoshihara S, Kon A, Kudo D, et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005;579(12):2722-2726.
28. Kakizaki I, Kojima K, Takagaki K, et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem. 2004;279(32):33281-33289.
29. Kakizaki I, Takagaki K, Endo Y, et al. Inhibition of hyaluronan synthesis in Streptococcus equi FM100 by 4-methylumbelliferone. Eur J Biochem. 2002;269(20):5066-5075.
30. Nakamura T, Funahashi M, Takagaki K, et al. Effect of 4-methylumbelliferone on cell-free synthesis of hyaluronic acid. Biochem Mol Biol Int. 1997;43(2):263- 268.
31. Kultti A, Pasonen-Seppanen S, Jauhiainen M, et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315(11):1914-1923.
32. Saito T, Dai T, Asano R. The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncol Lett. 2013;5(3):1068-1074.
33. Abate A, Dimartino V, Spina P, et al. Hymecromone in the treatment of motor disorders of the bile ducts: A multicenter, double-blind, placebo-controlled clinical study. Drugs Exp Clin Res. 2001;27(5-6):223-231.
34. Camarri E, Marchettini G. [Hymecromone in the treatment of symptoms following surgery of the bile ducts]. Recenti Prog Med. 1988;79(5):198-202.
35. Hoffmann RM, Schwarz G, Pohl C, et al. [Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility]. Dtsch Med Wochenschr. 2005;130(34-35):1938-1943.
36. Chen S, Cho M, Karlsberg K, et al. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J Biol Chem. 2004;279(46):48071-48078.
37. Crooke D FB, O'Kennedy R, McCormack T. Coumarins-multifaceted molecules with many analytical and other applications. Wiley & Sons, Inc.; 1997.
38. Keating G, O'Kennedy R. The chemistry and occurrence of coumarins. In: O'KennedyR, ThornesRD, ed. Coumarins Biology, Applications and Mode of action. Wiley & Sons, Inc.; 1997, 23-65.
39. Lokeshwar VB, Lopez LE, Munoz D, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010;70(7):2613-2623.
40. Benitez A, Yates TJ, Shamaldevi N, et al. Dietary supplement hymecromone and sorafenib: A novel combination for the control of renal cell carcinoma. J Urol. 2013;190(1):285-290.
41. Yates TJ, Knapp J, Gosalbez M, et al. C-X-C chemokine receptor 7: A functionally associated molecular marker for bladder cancer. Cancer. 2013;119(1):61-71.
42. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996;56(18):4096-4102.
43. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995;92(8):3439-3443.
44. Huss WJ, Gray DR, Tavakoli K, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia. 2007;9(11):938-50.
45. Patel SJ, Molinolo AA, Gutkind S, et al. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS One. 2013;8(4):e61848.
46. Rosenbluh J, Wang X, Hahn WC. Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol Sci. 2014;35(2):103-109.
47. Thakur R, Mishra DP. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med. 2013;17(4):449-456.
48. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5(1):a007898.
49. Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013;86(2):191-199.
50. Wei Q, Galbenus R, Raza A, et al. Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels. Cancer Res. 2009;69(6):2332-2339.
51. Thomsen FB, Brasso K, Klotz LH, et al. Active surveillance for clinically localized prostate cancer-a systematic review. J Surg Oncol. 2014;109(8):830-835.
52. Ciarlo M, Benelli R, Barbieri O, et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer. 2012;131(3):582-590.
53. Deng X, He G, Liu J, et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev. 2014;40(6):730-738.
54. Rabbani SA, Arakelian A, Farookhi R. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2013;2(5):625-635.
55. Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73(13):4112-4122.
56. Jokela TA, Kuokkanen J, Karna R, et al. Mannose reduces hyaluronan and leukocytes in wound granulation tissue and inhibits migration and hyaluronan-dependent monocyte binding. Wound Repair Regen. 2013;21(2):247-255.
57. Prehm P. Curcumin analogue identified as hyaluronan export inhibitor by virtual docking to the ABC transporter MRP5. Food Chem Toxicol. 2013;62:76-81.
58. Fujiwara R, Nakajima M, Yamanaka H, et al. Key amino acid residues responsible for the differences in substrate specificity of human UDPglucuronosyltransferase (UGT)1A9 and UGT1A8. Drug Metab Dispos. 2009;37(1):41-46.
59. Mano Y, Usui T, Kamimura H. Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos. 2004;25(8):339-344.
60. Miyauchi S, Sugiyama Y, Iga T, et al. Membrane-limited hepatic transport of the conjugative metabolites of 4-methylumbelliferone in rats. J Pharm Sci. 1988;77(8):688-692.
61. Mulder GJ, Brouwer S, Weitering JG, et al. Glucuronidation and sulfation in the rat in vivo. The role of the liver and the intestine in the in vivo clearance of 4-methylumbelliferone. Biochem Pharmacol. 1985;34(8):1325-1329.
62. Ratna S, Chiba M, Bandyopadhyay L, et al. Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology. 1993;17(5):838-853.
63. Grunwald V, DeGraffenried L, Russel D, et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002;62(21):6141-6145.
64. Choucair K, Ejdelman J, Brimo F, et al. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer. 2012;12:543.
65. Yang Y, Jiao L, Hou J, et al. Dishevelled-2 silencing reduces androgendependent prostate tumor cell proliferation and migration and expression of Wnt-3a and matrix metalloproteinases. Mol Biol Rep. 2013;40(7):4241- 4250.
66. Ding SP, Li JC, Jin C. A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol. 2003;9(3):584- 589.